For the bio-industry, the media is usually concerned that products that are not innovative will also increase in price, and drugs such as Melan and Valant are no longer cheap, and the US Food and Drug Administration approved biologics. Prohibited from use due to property rights disputes, etc.
The summary of these reports, the most important point is that other consumer goods used by the public are cutting prices, but drugs are getting more and more expensive. For a long time, the US biomedical industry has reached a tacit agreement with the government: unlike European countries, the US government rarely negotiates price reductions for drug prices, so the United States has higher drug expenditures. This in turn allows Americans with adequate health insurance to get the best innovative medicines and clinical trials as quickly as possible.
This is somewhat similar to the fact that the superpower maintains a standing army. Although it has to pay the price, it is also an obligation that must be fulfilled. If the United States provides financial support for a biopharmaceutical, people in other parts of the world can ultimately benefit from it. This logic makes sense. There is a theory that if Americans are willing, the United States will pay more to support the development of drugs, thus ensuring that global biopharmaceuticals continue to make progress.
During the entire medical reform process of President Obama, the above basic premise was hardly challenged. However, about the last year, the price increase of non-innovative drugs caused widespread dissatisfaction among the American people and became a national political topic. The American people are also gradually realizing the long-term fact that the wealthy people in the United States who have been squandered have lost momentum in the negotiation of drug prices, which has caused several major biopharmaceutical companies to make large profits. All of this makes the biomedical industry easy to target, especially in such a presidential election year.
The biomedical industry usually offers three rebuttals, but no one is attractive to Americans today: 1) medicines make up only a small fraction of the cost of medicine, and if used properly, it usually reduces the suffering of patients and can They save costs. 2) The cost of drug development is very high and unpredictable. Even some drugs cost billions, but ultimately they cannot recover the cost. 3) Innovation!
The third, very attractive, FierceBiotech recently announced the 14th annual Fierce 15 company list. The author has done a good job for you. It can be found that the biopharmaceutical industry is doing a lot of amazing research and development work, and some of them are likely to create miracles. Immuno-oncology may cure cancer, or at least turn cancer into a long-term, controlled process; microbes that give us psychological shadows are currently being evaluated to help us; gene therapy has the potential to address some genetic diseases and Reasonable development and delivery methods.
Therefore, companies in the Fierce 15 list have an important responsibility, and their innovative activities are trying to turn these into reality.
1.Adicet Bio
.png)
The company is designing the next generation of immune cell therapy
CEO: Aya Jakobovits
Address: Menlo Park, California
Established: 2014
Clinical Research Focus: Designing Immunocyte Therapy
Investors: OrbiMed, Novartis Venture Capital and Pontifax
Adicet did not disclose much of their technology or goals, and they aim to develop existing immune cells using controlled antigen receptors (CARs) and T cell receptors. Despite the success of immunotherapy in the treatment of blood cancer, Adicet is currently aiming at the higher goal of solid tumor therapy and considering its potential to treat autoimmune disorders.
In the field of immunotherapy, Adicet has successfully attracted the attention of some major biopharmaceutical companies. Only six months after entering the public eye, the company completed a $51 million Series A financing in January, with Novartis Ventures participating, and Adicet and Regeneron Pharmaceuticals ($REGN) made a secured deal.
Adicet first received $25 million from the deal with Regeneron for the development of existing cell therapies, a five-year R&D collaboration. Biomedical providers have the right to provide development and commercial power guarantees for an unknown number of experimental products, while Adicet can participate in the development and marketing process, or choose to use royalties.
2.Annexon Biosciences
.png)
The company uses new methods to better understand and reduce neurodegenerative autoimmune diseases.
CEO: Douglas Love
Address: South San Francisco, California
Established: 2011
Clinical research focus: Alzheimer's disease, Huntington's disease, glaucoma and autoimmune diseases
Investors: NEA, Correlation Ventures, Novartis Venture Capital, Clarus Ventures and Satter Investment Management
This preclinical biotech company is led by Genentech and Elan's retire, Doug Love. They are preparing to use classic complement inhibitor antibodies in the clinic to treat a range of diseases, such as central nervous disorders, autoimmune diseases and eye diseases, starting next year. Annexon has two major candidates, ANX005 for the treatment of central nervous disorders and autoimmune diseases, and ANX007 for the treatment of ocular diseases. Both drugs are used to inhibit a protein called C1q, which is the initial molecule of the classical pathway and prevents subsidy activation during neurodegeneration.
If you have a biotech company that studies Alzheimer's disease, you can't help but admire it, knowing that 99% of the research in this area has failed in the past decade. Since 2014, Love has been the CEO of Annexon. He said that he knows the failure to study Alzheimer's disease. If he thinks about facing this disease, he will naturally generate fear, but he thinks that they will be able to use the method. Success.
Although the removal of taurine or amyloid in the brains of Alzheimer's patients is currently the focus of most medical companies and biotech companies, Annexon is trying to stop synaptic degeneration rather than remembering it. After the disease is controlled, some of the debris in the brain is removed.
Tianeptine Intermediate,Tianeptine Api,Tianeptine Sodium,Tianeptine Sodium Intermediate
Shandong Bolode Bio-technology Co., Ltd. , https://www.bldpharma.com